CluePoints, provider of leading statistical and AI-driven software solutions, has announced Sylviane de Viron, its Data and Knowledge Manager, has been appointed to the Applied Clinical Trials (ACT) editorial advisory board. Sylviane de Viron’s appointment will help to advance knowledge of risk-based quality management (RBQM) throughout the clinical trial industry.
As a regular contributor to ACT, Sylviane’s recent articles have explored topics including KRI overload and how to detect fraud in clinical trials using statistical data monitoring. She is looking forward to working with her colleagues on the editorial advisory board to continue to drive quality and oversight in clinical trials.
Sylviane de Viron commented: “It’s an honor to join the editorial advisory board of Applied Clinical Trials. Our recent annual meeting was an inspiring exchange of ideas with experts from across the clinical research landscape. I look forward to contributing to thought-provoking discussions and helping shape the topics that will drive the evolution of clinical trials in the years ahead.”
ACT’s coverage spans from trial planning through to early-phase execution in the overall product development timeline, with a particular emphasis on the day-to-day operations of a trial. Its mission is to educate clinical operations executives on efficient development, recruitment, management and analysis for optimal end-to-end clinical trial execution.
Andrew Studna, Senior Editor, Applied Clinical Trials commented: “We are delighted Sylviane has agreed to join our editorial advisory board. Her thought-provoking articles always offer valuable insights into hot topics like central statistical monitoring and innovative uses of data. She is a perfect fit to ensure we continue to bring valuable content to stakeholders throughout the clinical research industry.”
As CluePoints’ Data and Knowledge Manager, Sylviane is responsible for creating knowledge on RBQM using CluePoints accumulated data. She has held various positions in the medical and pharmaceutical fields and has a PhD in Public Health from Maastricht University.
To learn more about CluePoints’ award-winning solutions, please visit www.cluepoints.com
About CluePoints
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. We are leveraging the potential of Artificial Intelligence using Advanced Statistics and Machine Learning to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R3), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation, you now have everything you need to adhere with global regulatory guidance. The result is positive clinical development outcomes, increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.
